Is Cannabis an Effective Treatment for Joint Pain? R.J

Total Page:16

File Type:pdf, Size:1020Kb

Is Cannabis an Effective Treatment for Joint Pain? R.J Is cannabis an effective treatment for joint pain? R.J. Miller1, R.E. Miller2 1Department of Pharmacology, ABSTRACT Introduction Northwestern University, Chicago; Cannabis has been used to treat pain Pain is one of the primary symptoms 2 Department of Internal Medicine, for thousands of years. However, since of joint disease and the major reason Division of Rheumatology, Rush University the early part of the 20th century, laws why patients seek medical advice. Un- Medical Center, Chicago, IL, USA. restricting cannabis use have limited fortunately, at this point in time, we Richard J. Miller, PhD its evaluation using modern scientific do not have a detailed understanding Rachel E. Miller, PhD criteria. Over the last decade, the situa- of how joint pain is generated under Please address correspondence to: tion has started to change because of the Dr Richard J. Miller, pathological conditions. When treating Department of Pharmacology, increased availability of cannabis in the osteoarthritis (OA) pain, non-steroidal Northwestern University, United States for either medical or recre- anti-inflammatory drugs (NSAIDs) are Chicago, IL, USA. ational purposes, making it important to usually the initial drugs of choice in pa- E-mail: [email protected] provide the public with accurate informa- tients with mild to moderate pain (1, 2). Received and accepted on September 9, tion as to the effectiveness of the drug for However, the chronic use of NSAIDS 2017. joint pain among other indications. The is often problematic, particularly with Clin Exp Rheumatol 2017; 35 (Suppl. 107): major psychotropic component of can- elder patients owing to gastrointestinal S59-S67. nabis is ∆9-tetrahydrocannabinol (THC), and renal side effects. Opiates may be © Copyright CLINICAL AND one of some 120 naturally occurring considered for patients who continue EXPERIMENTAL RHEUMATOLOGY 2017. phytocannabinoids. Cannabidiol (CBD) to have severe pain and who do not re- is another molecule found in herbal can- spond or cannot tolerate NSAIDs, and Key words: cannabis, nabis in large amounts. Although CBD can provide relief in a subset of patients phytocannabinoid, endocannabinoid, does not produce psychotropic effects, (1, 2), but tolerance, dependence and joint pain it has been shown to produce a variety other adverse effects such as consti- of pharmacological effects. Hence, the pation often occur during continuous overall effects of herbal cannabis repre- opioid use. Another serious problem is sent the collective activity of THC, CBD their abuse potential. Thus, even though and a number of minor components. The long term use of opiates may sometimes action of THC is mediated by two major produce pain relief, the current epi- G-protein coupled receptors, cannabi- demic of opiate addiction in the United noid receptor type 1 (CB1) and CB2, States clearly demonstrates the down- and recent work has suggested that other side of using opiates as anodynes over targets may also exist. Arachidonic acid extended periods of time. Although it derived endocannabinoids are the nor- is unlikely that the use of NSAIDS for mal physiological activators of the two the treatment of joint pain will be com- cannabinoid receptors. Natural phyto- pletely replaced in the near future, alter- cannabinoids and synthetic derivatives native treatments that are both effective have produced clear activity in a variety and safe would be extremely welcome. of models of joint pain in animals. These One way these may be developed is effects are the result of both inhibition of through a better understanding of the pain pathway signalling (mostly CB1) physiology and pharmacology of the and anti-inflammatory effects (mostly nerves that produce joint pain allow- CB2). There are also numerous anecdo- ing the rational development of novel tal reports of the effectiveness of smok- agents that selectively regulate their ac- ing cannabis for joint pain. Indeed, it is tivity. However, there are also currently the largest medical request for the use of several possible avenues available that the drug. However, these reports gener- might produce new agents for the treat- Funding: Richard Miller was supported ally do not extend to regulated clinical by the US National Institutes of Health/ ment of joint pain. One of the most ob- National Institute of Arthritis and Musculo- trials for rheumatic diseases. Neverthe- vious of these is cannabis. skeletal and Skin Diseases (NIH/NIAMS) less, the preclinical and human data that Cannabis is anything but a new drug, (R01AR064251). Rachel Miller was do exist indicate that the use of cannabis having been used by humans for medi- supported by NIAMS (K01AR070328). should be taken seriously as a potential cal purposes for thousands of years. Competing interests: none declared. treatment of joint pain. Some of the earliest evidence for Clinical and Experimental Rheumatology 2017 S-59 Cannabis for joint pain / R.J. Miller & R.E. Miller knowledge of the psychoactive prop- valuable source of tough fibrous mate- to the use of cannabis beside its psy- erties of cannabis can be found in the rial, which is the basis of hemp cloth. chotropic actions, including effects on Shen-nung pen-ts’ao ching, the world’s Indeed, another term for cannabis is appetite, pain, metabolism and inflam- oldest pharmacopeia, which describes “hemp” or “Indian hemp.” However, mation, Alzheimer’s disease, multi- Chinese practices from the time of Em- as discussed above, the plant has also ple sclerosis, stroke, traumatic brain peror Shen Nung (c. 2700 B.C.) (3). always been used for its beneficial me- injury, Parkinson’s disease, epilepsy, Later editions clearly describe the use dicinal effects. Pharmacologically ac- and various aspects of cancer (pain, of cannabis for a variety of conditions, tive parts of the plant include the leaves nausea, etc.). The list is endless. This including treating pain and inflamma- and flowering tops and particularly the raises an interesting question. Which tion (3). Indeed, cannabis has been con- resin (hashish, charas) that is secreted phytocannabinoids are responsible for tinuously used for the treatment of pain by glands (trichomes) in the stems, all of these therapeutic effects? Is THC in Asian countries from prehistory up flowers and leaves of the plant (5). The responsible for all of them or are there until the present day (3). The drug was drug can be smoked, eaten or extracted contributions of the other molecules as subsequently introduced into Europe using alcohol to produce a tincture. well? Smoking or eating cannabis will and the United States in the 19th century As organic chemistry developed in the obviously involve ingesting a large and soon became widely used for its an- early part of the 19th century, progress number of different phytocannabinoids. algesic and other properties (4, 5). began to be made in isolating the mole- Moreover, the exact combination of So what happened? As the reader may cules responsible for the pharmacologi- molecules ingested will depend on the be well aware, the highly restrictive cal effects of natural products. Starting strain of cannabis used, growth condi- legal status of cannabis in the United with morphine in 1805, numerous alka- tions and numerous other factors. It is States and Europe beginning in the ear- loids were isolated from different natu- therefore essential to deconvolute the ly part of the 20th century has made rig- ral sources, which helped to “explain” effects of all of the major phytocan- orous clinical evaluation of its effects pharmacological activities associated nabinoids on a particular endpoint such using modern criteria virtually impossi- with these materials. However, the iden- as pain if we wish to understand the po- ble. This situation has recently started to tity of the substances responsible for the tential effects of the drug. In particular, change. In spite of the fact that Federal pharmacological effects of herbal can- when considering the potential effects laws still list cannabis as a Schedule I nabis remained elusive until well into of cannabis, we should be interested in drug “having no medical utility”, many the 20th century, and it was not until 1964 the actions of both THC and CBD, the individual states have moved to make that ∆9-tetrahydrocannabinol (THC) two major phytocannabinoids, as well the drug legal for “medical” purposes, was shown to be the component of herb- as any beneficial interactions between or even for recreational use in some al cannabis responsible for producing its them, and whether cannabis is superior instances. It is therefore time to assess psychotropic effects (5). Interestingly, to either pure substance used by itself. whether we might expect cannabis to THC does not contain a nitrogen atom be effective for joint pain and, ancient and so is not an alkaloid, distinguish- The endocannabinoid system texts aside, what clear indications there ing it from many of the natural prod- What is the signal transduction mecha- are from the scientific point of view for ucts isolated from other plant sources. nism through which cannabinoids act? believing that it might be useful. It also explains its lipid like properties Two major observations “explain” the This raises several questions. First of that make it chemically difficult to work effects of THC. Two G-protein cou- all, what is cannabis and what active with. THC is the archetypal member of pled receptors have been identified that molecules does it contain? Second, the family of cannabis derived mole- mediate its cellular effects. These two what is the evidence that any of these cules which are known as cannabinoids receptors, known as cannabinoid recep- components might have beneficial ef- or, considering subsequent develop- tor type 1 (CB1) (8) and CB2 (9), have fects on joint pain? Third, is there any ments in the field of cannabis medicinal closely related amino acid sequences. evidence that these substances do ac- chemistry, phytocannabinoids, indicat- Their transmembrane regions are ap- tually ameliorate joint pain in animals ing that they are natural plant products proximately 70% similar (9), and they and humans? (6).
Recommended publications
  • Big-Catalogue-English-2020.Pdf
    PAS CH SIO UT N D ® CATALOGUE English SEED COMPANY Feminized, autoflower and regular cannabis seeds AMSTERDAM, ESTABLISHED 1987 for recreational and medical use. Amsterdam - Maastricht YOUR PASSION OUR PASSION DUTCH PASSION 02 Contents Welcome to Dutch Passion Welcome to Dutch Passion 02 Dutch Passion was the second Cannabis Seed Company in the world, established in Amsterdam in 1987. It is our mission to supply Bestsellers 2019 02 the recreational and medical home grower with the highest quality cannabis products available in all countries where this is legally Regular, Feminized and Autoflower 03 allowed. Cannabinoids 03 Medical use of cannabis 03 After many years of dedication Dutch Passion remains a leading supplier of the world’s best cannabis genetics. Our experienced Super Sativa Seed Club 04 team do their utmost to maintain the quality of our existing varieties and constantly search for new ones from an extensive network Special Cannabinoids / THC-Victory 05 of worldwide sources. We supply thousands of retailers and seed distributors around the world. Dutch Outdoor 06 High Altitude 09 CBD Rich 10 Dutch Passion have never been afraid to upset conventional thinking; we invented feminized seeds in the 1990’s and more recently Latin America 13 have pioneered the introduction of 10-week Autoflower seeds which have helped make life even easier for the self-sufficient Classics 14 cannabis grower. CBD-rich medical cannabis genetics is a new area that we are proud to be leading. Skunk Family 19 Orange Family 21 The foundation of our success is the genetic control we have over our strains and the constant influx of new genetics that we obtain Blue Family 24 worldwide.
    [Show full text]
  • Tasty THC: Promises and Challenges of Cannabis Edibles
    RTI Press Occasional Paper November 2016 Tasty THC: Promises and Challenges of Cannabis Edibles Daniel G. Barrus, Kristen L. Capogrossi, Sheryl C. Cates, Camille K. Gourdet, Nicholas C. Peiper, Scott P. Novak, Timothy W. Lefever, and Jenny L. Wiley RTI Press publication OP-0035-1611 This PDF document was made available from www.rti.org as a public service of RTI International. More information about RTI Press can be found at http://www.rti.org/rtipress. RTI International is an independent, nonprofit research organization dedicated to improving the human condition by turning knowledge into practice. The RTI Press mission is to disseminate information about RTI research, analytic tools, and technical expertise to a national and international audience. RTI Press publications are peer- reviewed by at least two independent substantive experts and one or more Press editors. Suggested Citation Barrus, D.G., Capogrossi, K.L., Cates, S.C., Gourdet, C.K., Peiper, N.C., Novak, S.P., Lefever, T.W., and Wiley, J.L. (2016). Tasty THC: Promises and Challenges of Cannabis Edibles. RTI Press Publication No. OP-0035-1611. Research Triangle Park, NC: RTI Press. http://dx.doi.org /10.3768/rtipress.2016.op.0035.1611 This publication is part of the RTI Press Research Report series. Occasional Papers are scholarly essays on policy, methods, or other topics relevant to RTI areas of research or technical focus. RTI International 3040 East Cornwallis Road PO Box 12194 ©2016 RTI International. All rights reserved. Credit must be provided to the author and source of the Research Triangle Park, NC publication when the content is quoted.
    [Show full text]
  • Annex 3 - Estimating Individual Consumption
    World Drug Report 2006 Volume I. Analysis Annex 3 - Estimating individual consumption Light tokers and chain-smokers has been found in Australia, where 60 per cent of annual users consumed the drug in the last month.265 A similar The estimated 162 million people who use cannabis do share is seen in the Netherlands (61 per cent), with not all use it at the same rate. Some of them may have slightly lower levels seen in France (52 per cent), Greece experimented with the drug once or twice, while others (53 per cent), Ireland (51 per cent), and Latvia (47 per consume the drug on a daily basis. It is estimated that cent).266 A slightly higher level is seen in the United 10 per cent of people who try cannabis will progress to Kingdom (63 per cent).267 daily use for some period of their lives, with a further 20 per cent to 30 per cent using on a weekly basis.263 This For a small share of these respondents, their use in the leaves, however, a large share of people whose use is less past month may have been the only time the drug was frequent. The prevalence of use tends to vary depending used in the past year. In other words, use in the past on the life-stage of the user. For example, about 60 per month does not mean that the drug was used every cent of French 19-year-old boys have tried cannabis, month of the previous year: ‘past month use’ does not and, of these, more than one in three uses 20 times a mean ‘monthly use’.
    [Show full text]
  • Cannabis Also Known As (Marijuana, Yarndi, Pot, Weed, Hash, Dope, Gunja, Joint, Stick, Chronic, Cone, Choof, Mull,420) By: Jeremiah Jamela Origin Origin
    Cannabis Also known as (Marijuana, yarndi, pot, weed, hash, dope, gunja, joint, stick, chronic, cone, choof, mull,420) By: Jeremiah Jamela Origin Origin • The history of Cannabis is long starting from Coastal farmers bringing cannabis from China to Korea in 2000 B.C. Cannabis came to south Asia between 1000 and 2000 B.C. Cannabis was then used regularly in India where Marijuana was mentioned in ancient poetry from that time period. Cannabis was brought into the Middle East between 1400 and 2000 B.C. where it was utilized by the Scythians • The Scythians then brought marijuana into southeast Russia as well as Ukraine from the Middle East. The drug was then traveled to Germany by the Germanic tribes and from there carried into Britain It then traveled through Africa and reached South America in the 19th century. Eventually it made its way into North America. The war on Drugs THe war on drugs • In 1937, the “Marihuana Tax Act” was passed. This federal law placed a tax on the sale of cannabis, hemp, or marijuana. • The Act was introduced by Rep. Robert L. Doughton of North Carolina and was drafted by Harry Anslinger. While the law didn’t criminalize the possession or use of marijuana, it included hefty penalties if taxes weren’t paid, including a fine of up to $2000 and five years in prison Transportation Transportation - legally • The Marijuana industry often transport their product in armored trucks • Often buying and selling kilos worth of weed making it hard to transport without risk • Often run out of weed quickly so they buy it in bulk and costly buy ahead of time Cost Price •Gram is typically $15 to $20 •Eighth is $30 to $45 • Ounce is $420 Type Choose Your High • Sativas have a higher level of THC than indicas, which results in a psychoactive and energetic mind-high this strain may cause feelings of alertness and optimism • Indica strains are believed to be physically sedating, perfect for relaxing with a movie or as a nightcap before bed.
    [Show full text]
  • DRONABINOL What Should You Do If You FORGET a What Other PRECAUTIONS Should Dose? You Follow While Using This Drug?
    DRONABINOL What should you do if you FORGET a What other PRECAUTIONS should dose? you follow while using this drug? Other NAMES : Marinol , delta – 9 - If you miss a dose of dronabinol, take it Before starting dronabinol, inform your tetrahydrocannabinol as soon as possible. However, if it is doctor if you have already had in the time for your next dose, do not double past adverse reactions to dronabinol, WHY is this drug prescribed? the dose, just carry on with your regular nabilone (Cesamet ) or marijuana schedule. (pot). Also, notify your doctor if you are Dronabinol is a narcotic drug used to allergic to sesame oil, if you have heart treat severe nausea and vomiting. It is What ADVERSE EFFECTS can this disease (hypertension, abnormal in a family of drugs called cannabinoids drug cause? What should you do heartbeat, angina), or a history of (eg. marijuana). It is also used to about them? emotional disorders such as depression, increase appetite and weight gain. bipolar disease (manic depression), and Dronabinol can cause unsteadiness, schizophrenia (psychosis, HOW should this drug be taken? dizziness, difficulty concentrating, hallucinations). drowsiness, euphoria, abnormal Dronabinol is available in 2.5 mg, 5 mg thinking, fatigue, anxiety, confusion, As this drug may cause some people to and 10 mg capsules. To increase hallucinations, and paranoia. become dizzy, drowsy or less alert than appetite and body weight, the usual Nausea, vomiting, abdominal pain, and normal, you should NOT drive, use initial dose is 2.5 mg twice daily. facial redness may also occur. machinery or do anything else that Depending on the results obtained, your could be dangerous if you are dizzy or doctor might decide to slowly increase These effects may go away during are not alert.
    [Show full text]
  • DRONABINOL- Dronabinol Capsule Actavis Pharma, Inc
    DRONABINOL- dronabinol capsule Actavis Pharma, Inc. ---------- DRONABINOL Capsules, USP 2.5 mg, 5 mg, 10 mg CIII Rx only DESCRIPTION Dronabinol is a cannabinoid designated chemically as (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9- trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol. Dronabinol has the following empirical and structural formulas: Dronabinol, the active ingredient in dronabinol capsules, USP, is synthetic delta-9-tetrahydrocannabinol (delta-9-THC). Delta-9-tetrahydrocannabinol is also a naturally occurring component of Cannabis sativa L. (Marijuana). Dronabinol is a light yellow resinous oil that is sticky at room temperature and hardens upon refrigeration. Dronabinol is insoluble in water and is formulated in sesame oil. It has a pKa of 10.6 and an octanol-water partition coefficient: 6,000:1 at pH 7. Capsules for oral administration: Dronabinol capsules are supplied as round, soft gelatin capsules containing either 2.5 mg, 5 mg, or 10 mg dronabinol. Each dronabinol capsule strength is formulated with the following inactive ingredients: 2.5 mg capsule contains gelatin, glycerin, sesame oil, and titanium dioxide; 5 mg capsule contains iron oxide red and iron oxide black, gelatin, glycerin, sesame oil, and titanium dioxide; 10 mg capsule contains iron oxide red and iron oxide yellow, gelatin, glycerin, sesame oil, and titanium dioxide. CLINICAL PHARMACOLOGY Dronabinol is an orally active cannabinoid which, like other cannabinoids, has complex effects on the central nervous system (CNS), including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of dronabinol and other cannabinoids.
    [Show full text]
  • Model Healthy Beverage Vending Agreement
    Butte County Public Health Department Note Because of limited data available on the safety of high potency Cannabis Products, the Butte County Public Health Department recommends that retailers not be allowed to carry Cannabis Products with THC content in excess of 20%. This is the one recommendation that is different from the original ordinance created by Public Health Institute. Authors Support - Lynn Silver, MD, MPH, Public Health Institute - Alisa Padon, PhD, Public Health Institute Contributors - Ted Mermin, JD - Leslie Zellers, JD - Immigrant Legal Resources Center - James Mosher, JD Getting it Right from the Start A project of the Public Health Institute 555 12th Street, Oakland, CA 94607 www.gettingitrightfromthestart.org Telephone: 510.285.5648 Fax: 510.285.5501 Email: [email protected] Acknowledgement This Model Ordinance was adapted in part from ChangeLab Solutions and the California Department of Public Health’s Model Tobacco Retail License Ordinance and “plug-ins,” which have been adopted by cities and counties across the State of California. We acknowledge and appreciate their important contributions, although they are not responsible for the content. We also thank the many individuals who contributed interview time and comments during the development process. Note The legal information provided in this model ordinance does not constitute legal advice or legal representation. For legal advice, readers should consult an attorney in their state. Table of Contents Introduction ......................................................................................................................
    [Show full text]
  • The Rise and Decline of Cannabis Prohibition the History of Cannabis in the UN Drug Control System and Options for Reform
    TRANSNATIONAL I N S T I T U T E THE RISE AND DECLINE OF CANNABIS PROHIBITION THE HISTORY OF CANNABIS IN THE UN DruG CONTROL SYSTEM AND OPTIONS FOR REFORM 3 The Rise and Decline of Cannabis Prohibition Authors Dave Bewley-Taylor Tom Blickman Martin Jelsma Copy editor David Aronson Design Guido Jelsma www.guidojelsma.nl Photo credits Hash Marihuana & Hemp Museum, Amsterdam/ Barcelona Floris Leeuwenberg Pien Metaal UNOG Library/League of Nations Archives UN Photo Printing Jubels, Amsterdam Contact Transnational Institute (TNI) De Wittenstraat 25 1052 AK Amsterdam Netherlands Tel: +31-(0)20-6626608 Fax: +31-(0)20-6757176 [email protected] www.tni.org/drugs www.undrugcontrol.info www.druglawreform.info Global Drug Policy Observatory (GDPO) Research Institute for Arts and Humanities Rooms 201-202 James Callaghan Building Swansea University Financial contributions Singleton Park, Swansea SA2 8PP Tel: +44-(0)1792-604293 This report has been produced with the financial www.swansea.ac.uk/gdpo assistance of the Hash Marihuana & Hemp Museum, twitter: @gdpo_swan Amsterdam/Barcelona, the Open Society Foundations and the Drug Prevention and Information Programme This is an Open Access publication distributed under (DPIP) of the European Union. the terms of the Creative Commons Attribution License The contents of this publication are the sole responsibility (http://creativecommons.org/licenses/by/2.0), which of TNI and GDPO and can under no circumstances be permits unrestricted use, distribution, and reproduction regarded as reflecting the position of the donors. in any medium, provided the original work is properly cited. TNI would appreciate receiving a copy of the text in which this document is used or cited.
    [Show full text]
  • Diabetes Mellitus
    PubMed (includes MEDLINE) Search conducted 09 January 2019 Query Results #1 "Diabetes Mellitus"[Mesh] OR diabet*[tiab] OR prediabet*[tiab] OR "type 1 630,566 DM"[tiab] OR "type 2 DM"[tiab] OR T1DM[tiab] OR T2DM[tiab] OR IDDM[tiab] OR MODY[tiab] OR NIDDM[tiab] OR "gestational DM"[tiab] #2 "Cannabis"[Mesh] OR "Cannabinoids"[Mesh] OR "Marijuana 52,197 Smoking"[Mesh] OR "Marijuana Use"[Mesh] OR "Marijuana Abuse"[Mesh] OR "Medical Marijuana"[Mesh] OR marijuana[tiab] OR marihuana[tiab] OR cannabis[tiab] OR cannabinoid*[tiab] OR tetrahydrocannabinol*[tiab] OR dronabinol*[tiab] OR THC[tiab] OR cannabidiol*[tiab] OR CBD[tiab] OR cannabinol*[tiab] OR "c.indica"[tiab] OR "c.sativa"[tiab] OR bhang[tiab] OR cannador[tiab] OR charas[tiab] OR eucannabinolide*[tiab] OR ganja[tiab] OR hash[tiab] OR hashish[tiab] OR hemp[tiab] OR epidiolex[tiab] OR marinol[tiab] OR "qcd 84924"[tiab] OR syndros[tiab] OR deltanyne[tiab] OR "abbott 40566"[tiab] OR namisol[tiab] OR dronabinolum[tiab] #3 #1 AND #2 599 #4 "Animals"[Mesh] NOT "Humans"[Mesh] 4,533,644 #5 #3 NOT #4 468 #6 #3 NOT #4 (Filter: 2008-present) 352 EMBASE (via Embase.com) Search conducted 09 January 2019 Query Results #1 'diabetes mellitus'/exp OR diabet*:ab,ti OR prediabet*:ab,ti OR 'type 1 1,042,067 DM':ab,ti OR 'type 2 DM':ab,ti OR T1DM:ab,ti OR T2DM:ab,ti OR IDDM:ab,ti OR MODY:ab,ti OR NIDDM:ab,ti OR 'gestational DM':ab,ti OR 'pregnancy induced DM':ab,ti #2 'Cannabis (genus)'/exp OR 'cannabinoid'/exp OR 'cannabis use'/exp OR 88,739 'cannabis addiction'/de OR 'cannabis-induced psychosis'/de OR marijuana:ab,ti
    [Show full text]
  • What Will Legal Marijuana Cost Employers?
    What Will Legal Marijuana Cost Employers? National Families in Action ThisAtlanta, page intentionally Georgia left blank. 1 2 What Will Legal Marijuana Cost Employers? A White Paper By Sue Rusche and Kevin Sabet, PhD The purpose of National Families in Action’s White Paper is to educate employers about how marijuana laws are changing, how these laws will affect employers’ ability to conduct business, and what employers can do to protect that ability. We contracted with Kevin Sabet, co-founder of Project SAM (Smart Approaches to Marijuana), to help write the White Paper. To begin, we assembled a group of experts from various fields to advise us on how the changing legal landscape will affect employers. All agree that costs will increase as changing marijuana laws present new challenges. Employers need to anticipate those challenges and plan ways to maintain profitability, productivity, safety, and flexibility while litigation and case law sort out state laws that conflict with federal laws and from state to state. The adage that an ounce of prevention is worth a pound of cure has never been more relevant. Employers have a significant opportunity to monitor both marijuana ballot initiatives that advocates are proposing and bills that state legislators are writing to protect their interests and those of their employees and the public. Please see Appendix A for information about National Families in Action, Project SAM, and our expert advisors. We gratefully acknowledge The Bodman Foundation for providing a grant to National Families in Action, which made it possible to produce this White Paper. 3 This page intentionally left blank.
    [Show full text]
  • Compliant Creation of Inhalable Compound Concentrate Products and Raw Pre-Rolls
    TECHNICAL BULLETIN August 18, 2021 Compliant Creation of Inhalable Compound Concentrate Products and Raw Pre-Rolls The purpose of this technical bulletin is to provide clarification to licensees regarding the compliant creation and subsequent testing of inhalable compound concentrate products and raw pre-rolls. Inhalable Compound Concentrate Products Inhalable compound concentrate products are defined as any products that are created by combining one or more marijuana concentrate products – and any other category of inhalable product (marijuana flower, kief, etc.) – into a final form intended for inhalation. Each marijuana concentrate product or inhalable product used to create the inhalable compound concentrate products is considered a “component.” “Final form” is defined as the form a marijuana product is in when it is available for sale by a marijuana sales location. Cultivators and sales locations are not permitted to add concentrate to pre-rolls or to create inhalable compound concentrate products. Commonly Created Inhalable Compound Concentrate Products • Moon rocks – marijuana buds or flower infused or coated with marijuana concentrate and subsequently rolled in kief. Sold by weight in gram increments. • Caviar – often the same as moon rocks but may not include the addition of kief. • Tarantula – marijuana flower/shake/trim, a coating of distillate, with kief and/or hash added, and then rolled into a pre-roll joint. Sold by the unit or by weight. • Infused pre-roll – marijuana flower/shake/trim along with the inclusion of distillate, addition of any concentrate, or addition of kief combined into a pre-roll joint. Sold by the unit or by weight. Previously identified as “pre-roll with concentrate added” in this Common Issues Bulletin.
    [Show full text]
  • Marijuana in Oregon: a Primer for Clinicians
    Legalized Marijuana in Oregon: A Primer for Clinicians Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist History • Originated Central Asia • 3000 BC: Chinese Emperor Shen Nung • Ancient Greeks and Romans familiar with cannabis • 1840’s: Dr. WB O’Shaughnessy, a surgeon working for the British East India Company • 1800’s: Hemp grown in US by President Washington • 1937: US marijuana tax law making it illegal Oregon Public Health Division 2 Marijuana: US Legal Status US DEA Controlled Substances Act Schedule 1 • High potential for abuse • No currently accepted medical use in US (federal level); clinical trials lacking 2018: State Laws • 30 States Medical MJ • 9 recreational Oregon Public Health Division 3 Oregon Medical Marijuana Act • December 1998: Oregon voters approved Ballot Measure 67 • Allows medical use of marijuana (for specific conditions) • Established a state-controlled permit system (the OMMP) • Protects patients and doctors from penalties Oregon Public Health Division 4 Marijuana Sales in Oregon • Jan 2014: Oregon Legislature approved Medical Marijuana Dispensaries (OHA regulates) • July 2015: recreational marijuana became legal • Oct 2015: early sales of retail marijuana allowed at medical dispensaries • Oct 2016: retail marijuana stores open (OLCC regulates) Oregon Public Health Division 5 Objectives • Be familiar with cannabis, cannabinoids, and medical conditions for which scientific evidence supports effectiveness. • Describe elements of Oregon’s clinical guidelines for physicians when recommending use of medical
    [Show full text]